ExtenZe Reviews: Leading Edge Health Publishes 2026 Label-Literacy Guide for Current Men’s Wellness Formula

Review of current U.S. retail labeling identifies 20 named active ingredients, including 18 components grouped within three proprietary blends totaling 554 mg; guide separates label facts, historical product research and independent ingredient studies

VICTORIA, British Columbia — September 30, 2026 — Leading Edge Health has published a 2026 label-literacy guide for ExtenZe after a review of current U.S. retail product information found that the label identifies 20 active ingredients but provides individual quantities for only zinc and folic acid. The remaining 18 components are grouped within three proprietary blends totaling 554 mg per serving.

A current U.S. retail Supplement Facts listing identifies 25 mg of zinc and 400 mcg of folic acid separately. It then lists a 60 mg blend containing DHEA and pregnenolone, a 25 mg blend containing black pepper, white pepper and ginger, and a 469 mg multi-ingredient blend containing botanicals, an amino acid and boron.

The disclosure means consumers can determine the total amount of each proprietary blend but cannot calculate the individual amount of DHEA, pregnenolone, L-arginine, maca, yohimbe, Tribulus, Epimedium or the other components within those blends.

That distinction is the central finding of the 2026 guide because most published ingredient studies use known quantities. Without individual amounts, research involving a defined dose cannot be directly matched with the amount contained in the finished ExtenZe formulation.

“Label transparency is most useful when consumers understand both what a Supplement Facts panel tells them and what it does not,” said Kevin Moore, Product Head at Leading Edge Health. “A proprietary blend can disclose its total weight and ingredients while still leaving individual quantities unknown. Independent ingredient studies should therefore remain tied to the doses and preparations researchers actually evaluated.”

What the Current Retail Label Discloses

The retail label reviewed for the guide identifies one serving and 30 servings per container.

Two nutrients are individually quantified:

Zinc — 25 mg

Folic acid — 400 mcg

The remainder of the listed active formulation is divided among three proprietary blends. The first provides 60 mg total and contains micronized DHEA and pregnenolone. The second provides 25 mg total and contains black pepper berries, white pepper fruit and ginger root.

The third provides 469 mg total and lists Tribulus extract, maca extract, Cnidium extract, yohimbe extract, L-arginine hydrochloride, Epimedium, Muira puama extract, pumpkin seed, stinging nettle extract, astragalus root, Fo-Ti extract, hops extract and boron.

Together, the three blend totals equal 554 mg. The same retail listing also carries a soy allergen warning, making allergen information another detail consumers should verify on the physical package.

What the Label Does Not Establish

A proprietary blend identifies the combined weight of several ingredients rather than the quantity contributed by each component. For ExtenZe, that means the 469 mg figure cannot be divided reliably among its 13 listed components based on the label alone.

L-arginine could account for one portion of that total and maca another, but the individual values are not specified. The same limitation applies to DHEA and pregnenolone within the 60 mg blend.

This matters when consumers encounter scientific research online.

If a study evaluates several grams of L-arginine, for example, the existence of L-arginine on the ExtenZe label does not demonstrate that the product supplies a comparable amount.

The guide therefore treats ingredient names as composition information, not evidence that research doses are reproduced by the finished formula.

Historical ExtenZe Research Has Important Limits

The 2026 review also identified a historical U.S. patent filing describing a limited pilot investigation involving an ExtenZe-labelled formulation.

The patent describes a group of 20 volunteers receiving one tablet daily for eight weeks. The filing characterizes the investigation as an initial pilot intended to provide information for the design of future studies.

A patent filing, however, is not equivalent to an independently published, peer-reviewed clinical trial.

The historical example also should not automatically be treated as evaluation of the current retail formulation. Product formulations, ingredient quantities and manufacturing specifications can change over time.

No independent, peer-reviewed clinical trial evaluating the current retail formula and current serving conditions was identified in the sources reviewed for this guide.

The historical pilot is therefore documented as part of the product’s research history rather than presented as confirmation of the current formulation.

L-Arginine: Published Research Uses Defined Gram-Level Doses

L-arginine is one of the ingredients named within the current 469 mg proprietary blend.

It is an amino acid involved in the body’s nitric-oxide pathway and has been studied extensively in vascular research.

One prospective randomized, double-blind human trial administered 6 grams of L-arginine to adults with hypertension and evaluated vascular measurements against placebo.

Another randomized trial involving healthy adults evaluated 6 grams or 12 grams per day for four weeks and found no statistically significant reduction in ambulatory blood pressure.

The two studies illustrate why ingredient evidence should not be reduced to a single conclusion.

More importantly for ExtenZe, both used known gram-level doses. Because the ExtenZe label groups L-arginine inside a 469 mg multi-ingredient blend without identifying its individual amount, a direct dose comparison cannot be made.

Maca: Controlled Research Includes Null Hormone Findings

Maca, or Lepidium meyenii, also appears within the 469 mg blend. A 12-week randomized, double-blind, placebo-controlled study involving healthy adult men evaluated 1,500 mg and 3,000 mg of maca per day.

Researchers measured several hormone concentrations and found no significant differences between maca and placebo for the measured hormone levels.

Those doses alone exceed the entire 469 mg ExtenZe blend. That does not establish that the amount of maca in ExtenZe is ineffective. It establishes that the published study used quantities that cannot be considered equivalent to an undisclosed portion of a smaller multi-ingredient blend.

The study therefore provides background about maca rather than product-level evidence for ExtenZe.

DHEA: Independent Research Should Remain Separate From Formula Claims

DHEA is one of two components identified within the 60 mg blend, together with pregnenolone.

The NIH Office of Dietary Supplements describes DHEA as a hormone produced naturally by the adrenal glands and notes that the body can convert it into other hormones.

NIH’s review of exercise-related research reports that the limited studies conducted in men did not demonstrate improvements in strength, aerobic capacity, lean body mass or measured testosterone concentrations compared with placebo.

NIH also notes that DHEA is prohibited in athletic competition by the NCAA and World Anti-Doping Agency.

For athletes subject to testing rules, the presence of DHEA is therefore an actionable label detail regardless of any broader product claims.

The ExtenZe label does not identify how the 60 mg blend is divided between DHEA and pregnenolone.

Yohimbe: Safety Information Is Relevant to Label Reading

Yohimbe extract appears within the 469 mg proprietary blend.

The National Center for Complementary and Integrative Health reports that research on yohimbe supplements in people remains limited and that the amount of its principal active compound can vary significantly among supplement products.

NCCIH also reports safety concerns involving changes in heart rhythm and blood pressure, along with other serious adverse events.

Medication use is particularly relevant. NCCIH advises people taking medicines to discuss yohimbe-containing supplements with a healthcare professional and specifically identifies interactions with certain antidepressant medications.

Because ExtenZe does not disclose the individual amount of yohimbe extract within the 469 mg blend, the guide does not assign a dose-specific conclusion to the finished formulation.

Zinc and Folate Are Individually Quantified

Unlike the proprietary-blend components, zinc and folic acid are separately quantified on the retail Supplement Facts listing.

The label identifies 25 mg of zinc and 400 mcg of folic acid per serving.

That distinction demonstrates why individual disclosure matters.

A consumer can compare 25 mg of zinc with dietary intake guidance or with zinc obtained from another supplement. The same calculation cannot be performed for L-arginine, maca or yohimbe because their individual amounts are not stated.

Consumers using multivitamins or other mineral products should consider the combined quantities from all sources rather than viewing each supplement independently.

Public Product Descriptions Use Different Levels of Detail

Leading Edge Health’s ExtenZe product page describes the formula using broader marketing terminology and refers to 26 compounds, while another section highlights a shorter group of principal ingredients.

A retail Supplement Facts listing provides a different level of detail by naming 20 active ingredients or components across the individually quantified nutrients and proprietary blends.

Those descriptions are not necessarily evidence of different formulations; one source may summarize components differently from another.

They do make the physical package important.

For dose-specific reporting, consumers should look at the current Supplement Facts panel supplied with the product rather than attempt to reconstruct the formula from marketing copy or older web pages.

What Consumers Should Check on the Package

The 2026 guide recommends checking several specific items rather than relying on a general instruction to “read the label.”

Consumers should verify:

• the current serving size and number of servings;

• 25 mg zinc and 400 mcg folic acid where those amounts appear on the package;

• the stated total amount of each proprietary blend;

• the ingredient names contained within those blends;

• the soy allergen warning where applicable;

• current directions and caution statements; and

• whether the physical package matches the product information being referenced online.

FDA requires dietary supplements to carry Supplement Facts information identifying serving size, dietary ingredients and applicable amounts. FDA does not approve dietary supplements for safety and effectiveness before they are sold.

Manufacturing and Regulatory Context

Manufacturing compliance and clinical evidence answer different questions. FDA’s current good manufacturing practice requirements address identity, purity, quality, strength and composition during dietary-supplement manufacturing and handling. They should not be interpreted as FDA approval of a finished supplement’s effectiveness.

FDA states that companies marketing dietary supplements are responsible for ensuring that products meet applicable safety standards and that labeling claims are truthful and not misleading.

The 2026 ExtenZe guide therefore separates manufacturing and labeling requirements from conclusions requiring product-specific clinical research.

Frequently Asked Questions

How many active ingredients are identified on the retail label reviewed?

The current U.S. retail listing reviewed for this guide identifies 20 named active ingredients or components, with zinc and folic acid individually quantified and 18 others distributed across three proprietary blends.

How much do the three proprietary blends contain?

The listed amounts are 60 mg, 25 mg and 469 mg, totaling 554 mg per serving.

Are the individual ingredients within those blends quantified?

No. The retail label gives the total amount of each blend but does not provide the individual quantity of each component.

Has the current formula been independently studied?

A historical patent filing describes a limited 20-person pilot investigation of an ExtenZe-labelled formulation. No independent, peer-reviewed clinical trial of the current retail formulation was identified in the sources reviewed for this guide.

Does ingredient research prove the finished formula produces the same findings?

No. Ingredient studies use defined preparations, amounts, participants and study conditions. Findings should not automatically be transferred to a proprietary multi-ingredient formula.

About Leading Edge Health

Leading Edge Health is a Canadian consumer-wellness company founded in 2001 and headquartered in Victoria, British Columbia. The company states that it began by serving Canada and the United States and now distributes products to customers in more than 130 countries.

Its current portfolio includes dietary supplements across multiple consumer wellness categories, including ExtenZe. The company’s Canadian corporate address is 300-1095 McKenzie Avenue, Victoria, British Columbia V8P 2L5.

References

1. Current U.S. ExtenZe retail Supplement Facts listing.

2. Leading Edge Health — current ExtenZe product information.

3. U.S. Patent Application US20090092687A1 — historical ExtenZe formulation and pilot example.

4. National Center for Complementary and Integrative Health — Yohimbe: Usefulness and Safety.

5. NIH Office of Dietary Supplements — Dietary Supplements for Exercise and Athletic Performance.

6. Gonzales GF, et al. Randomized, double-blind research examining maca in healthy adults.

7. Lekakis JP, et al. Randomized double-blind research examining oral L-arginine and vascular function.

8. U.S. Food and Drug Administration — dietary-supplement labeling and regulatory guidance.

Media Contact

Kevin Moore
Product Head
Leading Edge Health Inc.
300-1095 McKenzie Avenue
Victoria, British Columbia V8P 2L5
Canada
Phone: +1-866-261-8661 && support@buyextenze.com

Disclaimer

ExtenZe is a dietary supplement. Research referenced in this guide concerns either historical product documentation or individual ingredients studied under conditions that may differ from the current commercial formulation. Ingredient-level research should not be interpreted as clinical evaluation of the complete current formula.

Consumers should rely on the current physical Supplement Facts panel for serving size, ingredients, proprietary-blend totals, allergen information, directions and warnings. People taking medication, managing an existing medical condition or subject to competitive-sport restrictions should discuss relevant supplement ingredients with an appropriate healthcare professional.

These statements have not been evaluated by the U.S. Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.